SX-682 with Nivolumab for Maintenance Therapy in Patients with Unresectable, Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Inclusion Criteria

• Subjects must have the nature of the study explained to them
• Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, pharmacokinetic collections, study biopsies and other requirements of the study
• Subjects (or an acceptable proxy) must provide a signed and dated institutional review board (IRB)/independent ethics committee (IEC) approved written informed consent form (ICF) in accordance with regulatory and institutional guidelines for both the study and exploratory biomarker analysis obtained via paired biopsies
• Subjects (or an acceptable proxy) must provide a signed and dated Health Insurance Portability and Accountability Act (HIPAA) authorization
• The ICF and HIPAA authorization must be obtained before conduction and procedures that do not form a part of the subject’s normal care
• After signing the ICF and HIPAA Authorization, subjects will be evaluated for study eligibility during the Screening Period (no more than 28 days before study drug administration) according to the following further inclusion/exclusion criteria
• Male or female subjects, aged at least 18 years
• Have histologically or cytologically confirmed pancreatic ductal adenocarcinoma deemed unresectable (defined as metastatic or locally advanced disease) by the treating physician
• Completion of at least 16 weeks of first line chemotherapy without evidence of disease progression
• No planned radiation of the pancreas during the study period. Patients who completed radiation at the end of their first line chemotherapy course are eligible, but not until they completed their radiation therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Must have measurable disease with at least 1 unidimensional measurable lesion per Immune-Modified Response Evaluation Criteria in Solid Tumors (iRECIST)
• White blood cells (WBC) ≥ 3000/µL (within 14 days prior to first dose of study drug)
• Neutrophils ≥ 1500/µL (within 14 days prior to first dose of study drug)
• Platelets ≥ 100,000 > µL (within 14 days prior to first dose of study drug)
• Hemoglobin ≥ 9.0 g/dL in the absence of blood transfusion (within 14 days prior to first dose of study drug)
• Creatinine ≤ 1.5 mg/dL (within 14 days prior to first dose of study drug)
• Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) for subjects with no liver metastases ≤ 5 x ULN for subjects with liver metastases (within 14 days prior to first dose of study drug)
• Bilirubin ≤ 1.5 mg/dL ≤ 3.0 mg/dL for subjects with Gilbert’s disease (within 14 days prior to first dose of study drug)
• International normalized ratio or prothrombin time ≤ 1.5 x ULN unless receiving anticoagulation therapy (within 14 days prior to first dose of study drug)
• Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) ≤ 1.5 x ULN unless receiving anticoagulation therapy (within 14 days prior to first dose of study drug)
• Life expectancy of ≥ 12 weeks as judged by the treating physician
• Patient must consent for baseline and on treatment biopsies
• Patients must have baseline pulse oximetry ≥ 90% on room air

Exclusion Criteria

• Active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if these have been treated and there is no magnetic resonance imaging (MRI- except where contraindicated, in which case a CT scan is acceptable) evidence of progression for at least 8 weeks after treatment is complete and within 28 days prior to first dose of study drug administration. An MRI is not required to rule out brain metastases or leptomeningeal metastases. There must also be no requirement for high doses of systemic corticosteroids that could result in immunosuppression (>10 mg/day prednisone equivalents) for at least 2 weeks prior to study dry administration
• Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results. Specifically: * Subjects with active, non-infectious pneumonitis. * Subjects with interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management. * Subjects with clinically significant heart disease that affects normal activities. * Clinically significant cardiovascular/ cerebrovascular disease defined as cerebral vascular accident, stroke, carotid artery disease transient ischemic attach (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class > II) or serious cardiac arrhythmia. * Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast. * Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. * Subjects with a condition (including organ or bone marrow transplant) requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. * Use of other investigational drugs (drugs not marketed for any indication) or medications at immunosuppressive doses within 28 days before study drug administration. * Patients who received immunotherapy or investigational drug within 4 weeks prior to enrollment. * Patients who underwent major surgery within 4 weeks of enrollment (not including diagnostic laparoscopy) * History of myelodysplastic syndromes or myeloproliferative neoplasms. * History of or medication induced prolonged QT interval. * Any botanical preparation (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study or provide supportive care. Use of marijuana and its derivatives for treatment of symptoms related to cancer treatment, even if obtained by medical prescription or if its use (even without a medical prescription) has been legalized locally
• A history of Hepatitis B or C, either acute or chronic, as indicated by hepatitis B virus (HBV) surface antigen positivity, HBV core antibody positivity, or positive hepatitis C virus (HCV) antibody with reflex to positive HCV ribonucleic acid (RNA)
• Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
• Active tuberculosis (history of exposure or history of positive tuberculosis test plus presence of clinical symptoms, physical or radiographic findings)
• Electrocardiogram (EKG) demonstrating a Fridericia's corrected QT interval (QTc) interval > 470 msec or patients with congenital long QT syndrome
• History of allergy to study drug components (examples: hydroxpropylmethylcellulose phthalate (hypromellose phthalate or HPMCP), microcrystalline cellulose, sodium croscarmellose, sodium lauryl sulfate, and silicon dioxide)
• History of severe hypersensitivity reaction to any monoclonal antibody (grade ≥ 3 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5)
• History of anaphylaxis, or recent (within 5 months) history of uncontrolled asthma
• Women of childbearing potential (WOCBP) must use method(s) of contraception with a failure rate of less than 1% while on study and for 5 months after the last dose of SX-682 or nivolumab. A WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over age 45 in the absence of other biological or physiological causes
• Women under the age of 62 with a history of being postmenopausal must have a documented serum follicle stimulating hormone, (FSH) level > 40 mIU/mL
• Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of study drug
• Women must not be breastfeeding
• Men who are sexually active with women of child bearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year while on study and for a period at least 7 months after the last dose of study drug
• Women who are not of childbearing potential and azoospermic men do not require contraception
• Individuals who are incarcerated, compulsory detained or otherwise considered a vulnerable population